Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• NRAS-mutated (NRASmut) acute myeloid leukemia (AML) is a distinct subtype with largely unknown mutational landscape and prognostic factors.
• Understanding these factors is crucial for developing targeted therapies and improving patient outcomes.

Purpose of the Study:

• To elucidate the comprehensive mutational spectrum of NRASmut AML.
• To identify independent prognostic factors influencing remission, overall survival, and event-free survival in NRASmut AML patients.

Main Methods:

• Next-generation sequencing (NGS) was employed to analyze the mutational profile of 1,149 de novo AML cases.
• Mutational data from 152 NRASmut AML cases were analyzed.
• Multivariate analysis was performed to identify independent prognostic factors.

Main Results:

• NRAS mutations were identified in 13% (152/1,149) of de novo AML cases.
• The majority (89%) of NRASmut AML cases harbored at least one co-occurring mutation, frequently involving DNA methylation-related genes (62% incidence).
• Key co-mutations included TET2 (51%), ASXL1 (17%), NPM1 (14%), CEBPA (13%), DNMT3A (13%), FLT3-ITD (11%), and KIT (11%).
• Age ≥ 60 years and U2AF1 mutations were independent predictors of failure to achieve complete remission and poor overall survival.
• Age ≥ 60 years, non-M3 AML types, and higher-risk groups were associated with poor event-free survival (EFS), whereas allogeneic hematopoietic stem cell transplantation was linked to good EFS.

Conclusions:

• This study provides a detailed mutational spectrum for NRASmut AML, highlighting frequent co-mutations in epigenetic regulators.
• Age and specific mutations like U2AF1 are critical prognostic indicators for treatment response and survival.
• Allogeneic stem cell transplantation offers a survival benefit in NRASmut AML.